Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Berchem – page 161

2 112 clinical trials in Berchem, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Berchem at a glance
2 112
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

2 112 trials in Berchem

Open in trial search

Study on the Safety and Effects of Risdiplam for Adults and Children with Spinal Muscular Atrophy

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Risdiplam
  • Sponsor:F. Hoffmann-La Roche AG

Cardiac operation+1

Not recruiting

Study on Ilofotase Alfa to Prevent Kidney Damage in Patients Undergoing Open Heart Surgery

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ilofotase Alfa
  • Sponsor:AM-Pharma B.V.

Study of Adagrasib and Cetuximab for Patients with Advanced Colorectal Cancer with KRAS G12C Mutation After First-Line Therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Mirati Therapeutics Inc.

Pleural mesothelioma

Not recruiting

Study of Volrustomig with Carboplatin and Pemetrexed for Patients with Unresectable Pleural Mesothelioma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Study on the Long-term Effects of EDG-5506 for Adults and Adolescents with Becker Muscular Dystrophy

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:EDG-5506
  • Sponsor:Edgewise Therapeutics Inc.

Study on Venetoclax and Azacitidine for Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of Pembrolizumab and Olaparib with Chemoradiation for Patients with Newly Diagnosed Limited-Stage Small Cell Lung Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study Comparing Relatlimab-Nivolumab Combination with Regorafenib or Trifluridine-Tipiracil for Patients with Advanced Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol Myers Squibb International Corporation

Endometrial cancer

Not recruiting

Study Comparing Pembrolizumab and Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Multiple sclerosis+2

Not recruiting

Study on the Effectiveness and Safety of Ocrelizumab, Methylprednisolone, and Diphenhydramine Hydrochloride in Patients with Multiple Sclerosis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Methylprednisolone
  • Sponsor:F. Hoffmann-La Roche AG

Study Comparing SGN-B6A and Docetaxel for Adults with Previously Treated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Seagen Inc.

K-ras gene mutation+3

Not recruiting

Study of JDQ443 and Ribociclib in Combination for Adult Patients with Advanced Solid Tumors with KRAS G12C Mutation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Novartis Pharma AG

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Berchem

What the registry says about research in the country

01 Gastrointestinal Research

Clinical trials focusing on optimizing treatment strategies for patients with functional dyspepsia and related conditions like heartburn and reflux.

  • PPI De-prescribing Strategies
  • Alternative Treatment Approaches
  • Long-term Medication Management

Research evaluates various approaches to reducing proton pump inhibitor usage, including on-demand therapy and alternative treatments with alginate formulations.

02 Primary Care Innovation

Studies examining the effectiveness of different medication reduction strategies in the primary care setting, with a focus on improving patient outcomes.

  • Medication Optimization
  • Patient-Centered Care
  • Treatment Sustainability

The research aims to establish evidence-based protocols for discontinuing long-term medications when they may no longer be clinically indicated.

03 Therapeutic Management

Investigation of comparative effectiveness between different therapeutic approaches for chronic gastrointestinal conditions.

  • Treatment Comparison Studies
  • Clinical Outcomes Assessment
  • Quality of Life Impact

Research focuses on determining optimal strategies for transitioning patients from long-term medication use to alternative management approaches.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.